Hanmi Science Co Ltd
KRX:008930
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26 750
56 200
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Hanmi Science Co Ltd
Hanmi Science Co Ltd
Operating Income
Hanmi Science Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hanmi Science Co Ltd
KRX:008930
|
Operating Income
₩44.3B
|
CAGR 3-Years
13%
|
CAGR 5-Years
40%
|
CAGR 10-Years
9%
|
|
|
Yuhan Corp
KRX:000100
|
Operating Income
₩72.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
44%
|
CAGR 10-Years
0%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Operating Income
-₩37.5B
|
CAGR 3-Years
46%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Operating Income
₩255.8B
|
CAGR 3-Years
27%
|
CAGR 5-Years
23%
|
CAGR 10-Years
19%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Operating Income
₩4.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-14%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Operating Income
₩29.3B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
24%
|
CAGR 10-Years
15%
|
|
Hanmi Science Co Ltd
Glance View
Hanmi Science Co Ltd, rooted in the vibrant economic landscape of South Korea, charts a compelling narrative of innovation and strategic positioning in the pharmaceutical industry. This company, established in the mid-1960s, has evolved into a pivotal player by capitalizing on its robust research and development initiatives. It operates primarily through its subsidiary, Hanmi Pharmaceutical, leveraging cutting-edge biotechnology to engineer novel drug formulations. Their core business model rests on leveraging proprietary technologies to transition new chemical entities from the lab to the market, focusing on niche therapeutic areas such as oncology, diabetes, and autoimmune diseases. By pursuing an aggressive patent strategy, Hanmi Science not only underscores its commitment to innovation but also fortifies its revenue streams by licensing these patented technologies to global pharmaceutical heavyweights. Revenue generation for Hanmi Science is intrinsically tied to its capacity to scale its biotech advances. The company's income flows primarily from licensing agreements, where its patented drug technologies are adopted by international partners, bringing in a steady stream of licensing fees and milestone payments. Additionally, Hanmi selectively engages in product distribution across multiple international markets, further diversifying its revenue base. This strategic mix of monetary inflow via direct product sales and licensing agreements allows Hanmi Science to reinvest substantial portions back into research and development, fueling a cycle of continuous innovation and market competitiveness. Through this dynamic model, Hanmi Science dexterously navigates the complexities of the pharmaceutical landscape, cementing its status as an innovator and a reliable partner in global health advancements.
See Also
What is Hanmi Science Co Ltd's Operating Income?
Operating Income
44.3B
KRW
Based on the financial report for Sep 30, 2024, Hanmi Science Co Ltd's Operating Income amounts to 44.3B KRW.
What is Hanmi Science Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
9%
Over the last year, the Operating Income growth was -4%. The average annual Operating Income growth rates for Hanmi Science Co Ltd have been 13% over the past three years , 40% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet
